2018
DOI: 10.1038/s41564-017-0102-6
|View full text |Cite
|
Sign up to set email alerts
|

Deaminase-mediated multiplex genome editing in Escherichia coli

Abstract: In eukaryotes, the CRISPR-Cas9 system has now been widely used as a revolutionary genome engineering tool. However, in prokaryotes, the use of nuclease-mediated genome editing tools has been limited to negative selection for the already modified cells because of its lethality. Here, we report on deaminase-mediated targeted nucleotide editing (Target-AID) adopted in Escherichia coli. Cytidine deaminase PmCDA1 fused to the nuclease-deficient CRISPR-Cas9 system achieved specific point mutagenesis at the target si… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
225
2

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 165 publications
(231 citation statements)
references
References 31 publications
4
225
2
Order By: Relevance
“…To evaluate the base editing efficiency using Cas9 variants in C. glutamicum , AID was fused to the C‐terminal of the nickase form of VQR‐Cas9 and VRER‐Cas9 using a 100 aa linker, generating nVQR‐Cas9(D10A)‐AID and nVRER‐Cas9(D10A)‐AID, respectively. Although UGI that inhibits removal of uracil (an immediate product of cytidine deamination) from DNA is commonly used in eukaryotic base editing, its expression in bacteria may increase genome‐wide nonspecific mutagenesis and compromise genome integrity (Banno et al, ). Since we previously demonstrated that high‐efficiency base editing can be achieved without UGI in C. glutamicum (Y. Wang et al, ), UGI was not used for constructing base editors in this study.…”
Section: Resultsmentioning
confidence: 99%
“…To evaluate the base editing efficiency using Cas9 variants in C. glutamicum , AID was fused to the C‐terminal of the nickase form of VQR‐Cas9 and VRER‐Cas9 using a 100 aa linker, generating nVQR‐Cas9(D10A)‐AID and nVRER‐Cas9(D10A)‐AID, respectively. Although UGI that inhibits removal of uracil (an immediate product of cytidine deamination) from DNA is commonly used in eukaryotic base editing, its expression in bacteria may increase genome‐wide nonspecific mutagenesis and compromise genome integrity (Banno et al, ). Since we previously demonstrated that high‐efficiency base editing can be achieved without UGI in C. glutamicum (Y. Wang et al, ), UGI was not used for constructing base editors in this study.…”
Section: Resultsmentioning
confidence: 99%
“…55 Further validation of some BTK parts, such as the dCas9 and Cas9 systems, is needed to conclude that they will function reliably across diverse species. Other established broad-host-range tools—such as Tn7-transposon integration 46 , Group II intron-based gene disruption 57 , and emerging CRISPR methods for targeted mutagenesis 58 —could also be incorporated into the BTK-compatible Golden Gate framework in the future.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, CRISPR‐mediated nucleotide editing has been developed and as discussed below this method may also be used for manipulating gene expression strength. The first method described was called deaminase‐mediated targeted nucleotide editing (Target‐AID) [170] and was applied in the bacteria E. coli [171,172] and C. glutamicum [173]. Target‐AID relies on a cytidine deaminase fused to dCas9 and introduces C:G to T:A mutations at sequences defined by the sgRNA [170].…”
Section: Limitations Of Crispri and Future Directionsmentioning
confidence: 99%
“…Target‐AID relies on a cytidine deaminase fused to dCas9 and introduces C:G to T:A mutations at sequences defined by the sgRNA [170]. Target‐AID enables a high mutation efficiency and even simultaneous multiplex editing without introducing lethal double‐stranded DNA breaks, requiring a foreign DNA as a template and is independent of inefficient homologous recombination [171,173]. One application is the introduction of premature translational stop codons resulting in loss‐of‐function mutations [173].…”
Section: Limitations Of Crispri and Future Directionsmentioning
confidence: 99%